Tirzepatide

Plain-English version: Tirzepatide is a once-a-week shot that dramatically reduces appetite and blood sugar. It copies two natural gut hormones your body releases after eating, so you feel full sooner, eat less, and your blood sugar stays steadier. It is a fully approved prescription drug, not an experimental or gray-market compound.

Tirzepatide is a single synthetic peptide — a chain of 39 amino acids — engineered by Eli Lilly to be a dual incretin agonist. "Incretins" are hormones the gut releases when you eat that tell the pancreas to make insulin and tell the brain you are full. The two main incretins are GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). Tirzepatide is the first medicine designed to switch on both receptors at the same time^[1].

It received its first FDA approval in May 2022 for type 2 diabetes under the brand name Mounjaro, followed by approval in November 2023 for chronic weight management in adults with obesity (or overweight plus a weight-related condition) under the brand name Zepbound. These are the same molecule at identical doses; the two names exist mainly for insurance and prescribing reasons.

Why does adding GIP matter? Older drugs like semaglutide activate only the GLP-1 receptor. The theory — supported by the trial results below — is that engaging GIP as well improves how the body handles insulin and fat, and may soften some of the nausea that limits GLP-1-only drugs. The result has been the largest average weight loss of any approved anti-obesity medication to date.

One honest caveat on framing: because tirzepatide is an approved drug, the evidence bar here is genuinely high — multiple large randomized human trials, not the animal-only data common for unapproved research peptides. Where a claim on this page rests on receptor biology rather than a clinical outcome, we say so.

Plain-English version: Tirzepatide flips two appetite-and-blood-sugar switches (GIP and GLP-1) instead of one. That combination quiets hunger signals in the brain, slows how fast your stomach empties, and helps the pancreas release insulin only when blood sugar is high — so you eat less and your sugar control improves without much risk of dangerous low blood sugar.

The detailed pharmacology comes from receptor and cell studies (in-vitro work by Willard and colleagues, 2020), which is mechanism-level evidence rather than a human outcome trial^[1]. Those studies show tirzepatide is an imbalanced and biased dual agonist:

GLP-1 receptor activation

• Appetite suppression: GLP-1 signaling in the hypothalamus reduces hunger and increases fullness.
• Slower gastric emptying: Food leaves the stomach more slowly, so you stay full longer.
• Glucose-dependent insulin release: It boosts insulin from the pancreas only when blood sugar is elevated, which keeps the risk of hypoglycemia (dangerously low blood sugar) low.
• Glucagon suppression: It lowers the post-meal glucagon that would otherwise push blood sugar up.

Interestingly, tirzepatide binds the GLP-1 receptor about 5-fold more weakly than the body's own GLP-1, and it is "biased" toward cAMP signaling over beta-arrestin recruitment — meaning it triggers less receptor internalization and desensitization^[1]. In plain terms, the receptor stays responsive rather than getting quickly switched off.

GIP receptor activation

• Insulin sensitivity and fat handling: GIP acts on fat tissue and appears to improve how the body stores and uses fat and responds to insulin.
• Full-strength engagement: Unlike its weaker grip on GLP-1, tirzepatide engages the GIP receptor comparably to native GIP.
• Possible tolerability benefit: GIP co-agonism is one proposed reason the drug can deliver more weight loss without proportionally more nausea, though this is a hypothesis rather than settled fact.

Once-weekly by design

A C20 fatty di-acid tail lets the molecule bind to albumin, a carrier protein in the blood. That binding stretches its half-life to roughly 5 days (about 120 hours), which is what makes a single weekly injection possible^[1].

Plain-English version: In large, high-quality human trials tirzepatide produced the biggest average weight loss of any approved obesity drug, powerfully lowered blood sugar in type 2 diabetes, beat semaglutide head-to-head, and improved cardiometabolic markers. Below, each benefit is laid out as claim → mechanism → who was studied → effect size → limitation.

Weight loss (obesity without diabetes)

Claim: Tirzepatide drives large, dose-dependent weight loss. Mechanism: combined GIP/GLP-1 appetite suppression and slowed gastric emptying reduce calorie intake. Population: SURMOUNT-1 randomized 2,539 adults with obesity or overweight (without diabetes) and followed them for 72 weeks. Effect size: mean weight change was -15.0% (5 mg), -19.5% (10 mg), and -20.9% (15 mg) versus -3.1% for placebo; at 15 mg roughly 91% lost at least 5% of body weight and 57% lost at least 20%^[2].

Dose	Mean weight loss	Lost ≥5%	Lost ≥20%
Placebo	-3.1%	~35%	~3%
5 mg	-15.0%	~85%	~30%
10 mg	-19.5%	~89%	~47%
15 mg	-20.9%	~91%	57%

Limitation: results reflect 72 weeks of continued treatment alongside lifestyle counseling; weight tends to return after stopping, and individual response varies widely.

More effective than semaglutide (head-to-head)

Claim: Tirzepatide produces more weight loss than semaglutide. Mechanism: dual GIP/GLP-1 action versus GLP-1 alone. Population: SURMOUNT-5 randomized 751 adults with obesity (without diabetes) to max-tolerated tirzepatide (10 or 15 mg) or max-tolerated semaglutide (1.7 or 2.4 mg) for 72 weeks. Effect size: least-squares mean weight change was -20.2% for tirzepatide versus -13.7% for semaglutide (P<0.001) — a statistically significant advantage^[3]. Limitation: this measured weight, not long-term cardiovascular events; semaglutide has its own dedicated outcomes data that tirzepatide is still accumulating.

Type 2 diabetes: blood sugar control

Claim: Tirzepatide is among the most potent glucose-lowering drugs available. Mechanism: glucose-dependent insulin release plus glucagon suppression and weight loss. Population: SURPASS-2 randomized 1,879 adults with type 2 diabetes inadequately controlled on metformin, over 40 weeks, head-to-head against semaglutide 1 mg. Effect size: HbA1c (a 3-month average blood-sugar measure) fell by roughly 2.0–2.6% across the 5/10/15 mg doses, superior to semaglutide 1 mg, with greater weight loss too; in a prespecified analysis, 60% of the 15 mg group reached HbA1c at or below 6.5% with at least 10% weight loss and no severe hypoglycemia, versus 22% on semaglutide 1 mg^[4]. SURPASS-1 established the same efficacy as monotherapy in drug-naive patients^[5]. Limitation: the semaglutide comparison used the 1 mg diabetes dose, not the higher weight-management dose.

Cardiovascular-risk population and safety signals

Claim: Tirzepatide lowers glucose with weight loss and reassuring cardiovascular signals in higher-risk patients. Mechanism: weight loss plus improvements in blood pressure and lipids. Population: SURPASS-4 studied type 2 diabetes patients with elevated cardiovascular risk, comparing tirzepatide to insulin glargine. Effect size: tirzepatide was superior for glucose lowering and produced weight loss instead of the weight gain typical with insulin, with no excess of major adverse cardiovascular events in that trial^[6]. Limitation: SURPASS-4 was not a dedicated cardiovascular-outcomes trial designed to prove event reduction; that larger outcomes evidence is still maturing.

For the broader landscape, see our peptides for weight loss guide, compare directly at semaglutide, or look ahead to the triple agonist retatrutide.

Plain-English version: You inject tirzepatide under the skin once a week. You must start low (2.5 mg) and step the dose up slowly — never jump straight to a high dose — because the biggest side effects come from ramping too fast. The 2.5 mg starting dose is a warm-up, not a treatment dose.

The dosing below reflects the FDA labels and trial protocols. Tirzepatide is a prescription medicine; doses and titration should always be set by your prescriber. This is not a self-dosing guide.

Standard titration schedule

Phase	Dose (once weekly)	Minimum duration	Notes
Starting	2.5 mg	4 weeks	Titration only — not a maintenance dose
Step 1	5 mg	4+ weeks	First possible maintenance dose
Step 2	7.5 mg	4 weeks	Titration dose
Step 3	10 mg	4+ weeks	Second possible maintenance dose
Step 4	12.5 mg	4 weeks	Titration dose
Maximum	15 mg	Maintenance	Highest approved dose

Each increase is 2.5 mg, no more often than every 4 weeks^[2]. Reaching 15 mg therefore takes a minimum of about 20 weeks. Not everyone needs the maximum — many people do well at 5 or 10 mg, and the right maintenance dose depends on response and tolerability.

A randomized trial has now tested what happens if you later lower that maintenance dose instead of holding it or stopping: see what lowering your tirzepatide dose to 5 mg costs for the SURMOUNT-MAINTAIN results.

How it is given

• Route: subcutaneous (under the skin) injection into the abdomen, thigh, or upper arm; rotate sites.
• Timing: any day, any time, with or without food — but pick a consistent weekly day.
• Changing your day: you can move your injection day as long as your last dose was at least 3 days (72 hours) earlier.
• Missed dose: if it is within 4 days (96 hours), take it as soon as possible; if more than 4 days late, skip it and resume on the next scheduled day. Do not double up.

Commercial pens vs. research-grade powder

The approved products (Mounjaro and Zepbound) come as pre-filled, single-use auto-injector pens — no measuring or mixing required. Store unopened pens refrigerated at 2–8°C (36–46°F); an unused pen can sit at room temperature up to 30°C (86°F) for up to 21 days, then must be discarded. Do not freeze, and do not use if the solution is cloudy or discolored.

Some people encounter lyophilized (freeze-dried) "research-grade" tirzepatide that requires reconstitution. We cover the legal and quality caveats of that market in the Sourcing & Quality section below. If you are working with powder, the arithmetic is straightforward:

Worked reconstitution example. Suppose you have a vial containing 10 mg of tirzepatide and you add 1 mL of bacteriostatic water. Concentration = 10 mg ÷ 1 mL = 10 mg/mL. To draw a 5 mg dose: 5 mg ÷ 10 mg/mL = 0.5 mL, which is 50 units on a standard U-100 insulin syringe. For a 2.5 mg starting dose from the same vial: 2.5 mg ÷ 10 mg/mL = 0.25 mL = 25 units. Our peptide calculator automates this math.

Note that milligram numbers are not comparable across drugs: tirzepatide's 2.5–15 mg range is not "stronger" or "weaker" than semaglutide's 0.25–2.4 mg range — they are different molecules with different potencies.

Plain-English version: The most common side effects are stomach-related — nausea, diarrhea, constipation, and vomiting — and they are usually worst while you are stepping the dose up, then ease off. Serious risks are uncommon but real, including pancreatitis, gallbladder problems, and a boxed warning about thyroid tumors seen in rodents. Some people should not take it at all.

Tirzepatide has been studied in Phase 3 trials involving well over 10,000 people, so its safety profile is unusually well characterized for a compound in this space. Roughly 4–7% of trial participants stopped due to side effects, meaning most tolerated it well enough to continue.

Common side effects (dose-escalation related)

Side effect	Approx. frequency	Typical severity	Timing
Nausea	12–24%	Mild–moderate	Worst during titration; improves at a stable dose
Diarrhea	12–17%	Mild–moderate	Most common during dose increases
Decreased appetite	5–11%	Mild	Part of how the drug works
Vomiting	5–9%	Mild–moderate	More common at higher doses
Constipation	5–7%	Mild	Related to slowed gastric emptying
Abdominal pain	5–7%	Mild	Usually transient
Injection-site reactions	3–5%	Mild	Transient redness or itching

These gastrointestinal effects are the most common adverse events in pooled Phase 3 data and are generally mild to moderate^[4]. Practical steps that help: follow the titration schedule (do not skip levels), eat smaller meals, avoid greasy/high-fat foods, and stay hydrated. If symptoms are severe, a prescriber may hold a dose level longer before increasing.

Serious risks

• Thyroid C-cell tumors (boxed warning): Rodents developed thyroid C-cell tumors with drugs in this class. This has not been confirmed in humans at clinical doses, but tirzepatide is contraindicated for anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2)^[6].
• Pancreatitis: Acute pancreatitis (inflammation of the pancreas) has been reported. Seek care for severe, persistent abdominal pain that radiates to the back; the drug should be stopped if pancreatitis is suspected.
• Gallbladder / biliary events: Gallstones and cholecystitis occur more often, largely tied to rapid weight loss.
• Hypoglycemia: Low on its own, but the risk rises sharply when combined with insulin or sulfonylureas — those medications often need dose reduction.
• Muscle (lean mass) loss: As with any large weight loss, a meaningful share of what is lost can be lean mass. Resistance training and adequate protein help preserve muscle.

Who should not take it

• Personal or family history of medullary thyroid carcinoma (MTC) or MEN2.
• Known hypersensitivity to tirzepatide.
• Pregnancy and breastfeeding (no established safety).
• Severe gastroparesis (already-delayed stomach emptying).

Drug interactions to flag with your clinician: insulin and sulfonylureas (hypoglycemia risk); oral contraceptives (delayed gastric emptying can reduce absorption — a backup or non-oral method may be advised, especially during titration); and oral medicines with a narrow therapeutic window such as warfarin, where absorption timing matters.

Plain-English version: Tirzepatide (dual GIP/GLP-1) generally out-loses semaglutide (GLP-1 only), which is the other leading approved option. Newer drugs in trials add a third target for potentially even more weight loss.

Feature	Tirzepatide (Zepbound/Mounjaro)	Semaglutide (Wegovy/Ozempic)
Mechanism	Dual agonist (GIP + GLP-1)	Single agonist (GLP-1)
Max approved dose	15 mg weekly	2.4 mg weekly
Head-to-head weight loss	-20.2%	-13.7%
Developer	Eli Lilly	Novo Nordisk
Dosing frequency	Once weekly SC	Once weekly SC

The head-to-head figures come from SURMOUNT-5, where tirzepatide produced roughly 50% more weight loss than semaglutide over 72 weeks^[3]. For the full breakdown see our tirzepatide vs semaglutide comparison.

Where the field is heading

• Retatrutide: an investigational triple agonist (GIP + GLP-1 + glucagon) posting even larger weight-loss numbers in trials — not yet approved.
• Semaglutide: the established GLP-1-only benchmark, with its own dedicated cardiovascular-outcomes data.

Plain-English version: The safe, legal way to get tirzepatide is a prescription for Mounjaro or Zepbound from a licensed clinician. Anything sold online as "research tirzepatide" for a fraction of the price sits outside FDA oversight, and you cannot verify what is actually in the vial.

The approved route

Tirzepatide is a prescription drug. Mounjaro and Zepbound are manufactured by Eli Lilly under FDA regulation, arrive as sealed single-use pens with verified identity, purity, and dose, and come with clinician oversight and (often) insurance pathways. This is the route the clinical evidence on this page actually supports.

The gray market — and why it is risky

You may see lyophilized tirzepatide sold "for research use only" and "not for human consumption." Buying these products carries real problems:

• No FDA oversight: identity, dose accuracy, sterility, and endotoxin content are unverified unless independently tested.
• Legal ambiguity: selling research chemicals for human use violates FDA rules, and marketplace availability shifts with enforcement.
• Dosing error risk: reconstituting powder by hand introduces measurement mistakes that pre-filled pens eliminate.

If you are evaluating a research-grade product

Insist on a batch-specific third-party Certificate of Analysis (COA) showing HPLC purity (ideally ≥98%) and mass-spectrometry identity confirmation, plus endotoxin (LAL) testing for anything injectable. Reject vendors offering no COA, pre-mixed liquid, prices far below market, or "for human use" labeling. Store lyophilized powder cold and dark; keep reconstituted solution refrigerated and never freeze it. See our peptide storage guide and the beginner's guide for context. None of this makes an unapproved source equivalent to a prescription — it only reduces, not removes, the uncertainty.